EyeGene Past Earnings Performance
Past criteria checks 0/6
EyeGene's earnings have been declining at an average annual rate of -29.1%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 4% per year.
Key information
-29.1%
Earnings growth rate
-18.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 4.0% |
| Return on equity | -34.9% |
| Net Margin | -675.3% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How EyeGene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,125 | -21,106 | 7,422 | 20,580 |
| 30 Sep 23 | 3,195 | -20,052 | 8,589 | 20,457 |
| 30 Jun 23 | 4,277 | -23,840 | 8,688 | 19,833 |
| 31 Mar 23 | 5,007 | -27,174 | 9,257 | 18,104 |
| 31 Dec 22 | 5,293 | -25,953 | 9,612 | 16,343 |
| 30 Sep 22 | 4,735 | -46,329 | 11,193 | 25,184 |
| 30 Jun 22 | 3,960 | -51,078 | 10,857 | 30,783 |
| 31 Mar 22 | 3,494 | -37,678 | 9,171 | 30,508 |
| 31 Dec 21 | 3,242 | -34,569 | 7,616 | 27,994 |
| 30 Sep 21 | 3,291 | -14,815 | 6,250 | 18,746 |
| 30 Jun 21 | 3,363 | -8,830 | 5,434 | 10,767 |
| 31 Mar 21 | 3,280 | -14,127 | 5,190 | 8,166 |
| 31 Dec 20 | 3,363 | -14,863 | 5,395 | 8,823 |
| 30 Sep 20 | 3,560 | -14,598 | 5,465 | 7,116 |
| 30 Jun 20 | 4,148 | -10,746 | 5,413 | 6,763 |
| 31 Mar 20 | 4,245 | -10,409 | 5,769 | 6,559 |
| 31 Dec 19 | 4,245 | -8,740 | 5,359 | 5,095 |
| 30 Sep 19 | 4,023 | -5,381 | 4,033 | 4,665 |
| 30 Jun 19 | 3,567 | -5,902 | 4,508 | 4,078 |
| 31 Dec 18 | 2,035 | -5,908 | 4,670 | 3,783 |
Quality Earnings: A185490 is currently unprofitable.
Growing Profit Margin: A185490 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A185490 is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare A185490's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A185490 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A185490 has a negative Return on Equity (-34.87%), as it is currently unprofitable.